首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2103000

藥物基因組學檢測市場：策略性洞察與預測（2026-2035）

Pharmacogenomics Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計藥物基因組學檢測市場將從 2026 年的 111 億美元成長到 2035 年的 233.4 億美元，複合年成長率為 8.6%。

藥物基因組學檢測使醫療專業人員能夠根據個體的基因譜最佳化藥物選擇和劑量。透過識別影響藥物代謝、療效和毒性的基因變異，藥物基因組學檢測可以改善治療效果，同時減少藥物不良反應。精準醫療的日益普及、分子診斷技術的進步以及藥物附加檔和臨床指南中藥物基因體學基因組學生物標記的日益廣泛應用，正在加速藥物基因組學檢測的市場滲透。醫療專業人員、製藥公司和診斷實驗室持續投資於藥物基因組學檢測，以改善治療決策並確保患者安全。

市場促進因素

個人化醫療的普及

全球向個人化醫療的轉變正顯著推動藥物基因組學檢測需求的成長。臨床醫生擴大利用基因資訊來個人化藥物選擇、最佳化劑量並改善多個治療領域的治療效果。

精準腫瘤學的發展

在癌症治療領域，基於生物標記的療法越來越受到重視。藥物基因組學檢測使腫瘤學家能夠識別最有可能從標靶治療中獲益的患者，同時最大限度地減少治療相關的毒性，這推動了此類檢測在腫瘤學領域的廣泛應用。

人們對藥物不良反應的認知不斷提高

藥物不良反應仍然是全球住院治療和醫療保健成本的主要原因之一。藥物基因組學檢測有助於識別影響藥物代謝的遺傳風險因素，使醫生能夠開立更安全、更有效的藥物。

在製藥領域不斷拓展的應用

製藥和生物技術公司正擴大將藥物基因體學標記納入臨床試驗，以改善患者分層、提高藥物發現效率並支持伴隨診斷的開發。

市場限制因素

臨床實務中缺乏認知

儘管越來越多的證據支持藥物基因體學，但醫療保健系統在醫生教育和意識方面的不一致性正在減緩其在常規臨床應用中的進展。

與保險報銷相關的問題

公共和私人醫療保健系統對藥物基因組學檢測的保險覆蓋範圍差異很大，這限制了某些市場的患者獲得檢測的機會。

複雜數據解讀

藥物反應受多種遺傳和環境因素影響。解讀藥物基因體學檢測結果需要專業知識和完善的臨床決策支援系統。

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
市場規模表現分析
市場預測分析
藥物基因體學生態系統概述
精準醫療和個人化治療的現狀
測試數量分析
用戶採納狀況分析
藥物-基因交互作用整體情況
伴隨診斷和補充診斷概述
臨床效用和醫療結果的評估

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

藥物基因組檢測領域的新興技術
產品創新分析
基於次世代定序的藥物基因體學學進展
多重基因型鑒定和麵板檢測技術的創新
臨床決策支援系統的整合
臨床試驗分析
管道分析
將人工智慧整合到藥物基因組學分析中
數位健康與電子健康記錄的整合
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：藥物基因體學檢測市場：展望分析

分析：按技術平台
分析：按基因家族
分析：透過調查方法
分析：按治療領域
分析：透過臨床應用
分析：透過測試環境
分析：按最終用戶

第9章：藥物基因組學檢測市場：細分市場分析

按產品/服務
- 裝置
- 試劑和耗材
- 軟體和臨床決策支援解決方案
- 藥物基因組檢測服務
透過技術
- 聚合酵素鏈鎖反應（PCR）
- DNA微陣列
- 次世代定序（NGS）
- 桑格定序
- 其他技術
依基因家族
- CYP450基因
- HLA基因
- TPMT基因
- DPYD基因
- UGT基因
- 其他藥物基因體學學標記物
按治療區域
- 腫瘤學
- 精神病學和心理健康
- 循環系統
- 神經病學
- 疼痛管理
- 感染疾病
- 其他治療領域
最終用戶
- 醫院和醫療系統
- 診斷檢查室
- 學術研究機構
- 製藥和生物技術公司
- 其他最終用戶

第10章：藥物基因體學檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：藥物基因體學檢測市場：國別分析

美國
加拿大
德國
英國
法國
荷蘭
瑞士
中國
日本
韓國
印度
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

QIAGEN NV
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Illumina, Inc.
Myriad Genetics, Inc.
Natera, Inc.
Labcorp Holdings Inc.
Quest Diagnostics Incorporated
SOPHiA GENETICS SA
Bio-Rad Laboratories, Inc.
Invitae Corporation
Genomind, Inc.
OneOme, LLC
GeneDx, LLC
Molecular You Corporation

第14章：藥物基因組學檢測市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-008395

The Pharmacogenomics Testing Market is anticipated to grow at a CAGR of 8.6% from USD 11.1 billion in 2026 to USD 23.34 billion in 2035.

Pharmacogenomics testing enables healthcare providers to optimize drug selection and dosage based on an individual's genetic profile. By identifying genetic variations that influence drug metabolism, efficacy, and toxicity, pharmacogenomic testing improves treatment outcomes while reducing adverse drug reactions. Growing implementation of precision medicine, advances in molecular diagnostic technologies, and increasing incorporation of pharmacogenomic biomarkers into drug labels and clinical guidelines are accelerating market adoption. Healthcare providers, pharmaceutical companies, and diagnostic laboratories continue investing in pharmacogenomic testing to improve therapeutic decision-making and patient safety.

Market Drivers

Increasing Adoption of Personalized Medicine

The global shift toward individualized healthcare is significantly increasing demand for pharmacogenomic testing. Clinicians are increasingly using genetic information to personalize medication selection, optimize dosing, and improve treatment effectiveness across multiple therapeutic areas.

Growth of Precision Oncology

Cancer treatment increasingly relies on biomarker-guided therapies. Pharmacogenomic testing enables oncologists to identify patients most likely to benefit from targeted therapies while minimizing treatment-related toxicity, driving widespread adoption in oncology care.

Rising Awareness of Adverse Drug Reactions

Adverse drug reactions remain a major cause of hospitalizations and healthcare costs worldwide. Pharmacogenomic testing helps identify genetic risk factors that influence drug metabolism, allowing physicians to prescribe safer and more effective medications.

Expanding Pharmaceutical Applications

Pharmaceutical and biotechnology companies are increasingly incorporating pharmacogenomic biomarkers into clinical trials to improve patient stratification, enhance drug development efficiency, and support companion diagnostic development.

Market Restraints

Limited Clinical Awareness

Despite growing evidence supporting pharmacogenomics, physician education and awareness remain inconsistent across healthcare systems, slowing routine clinical implementation.

Reimbursement Challenges

Coverage for pharmacogenomic testing varies considerably among public and private healthcare systems, limiting patient access in several markets.

Complex Data Interpretation

Drug response is influenced by multiple genetic and environmental factors. Interpretation of pharmacogenomic results requires specialized expertise and robust clinical decision-support systems.

Market and Technology Insights

The global pharmacogenomics testing market can be segmented by product & service, technology, gene family, therapeutic area, end user, and geography.

By product & service, the market includes instruments, reagents & consumables, software & clinical decision support solutions, and pharmacogenomic testing services. Reagents and consumables account for a substantial share because of recurring laboratory testing requirements, while software platforms are gaining importance through integration with electronic health records and clinical decision support.

By technology, the market comprises polymerase chain reaction (PCR), DNA microarrays, next-generation sequencing (NGS), Sanger sequencing, and other molecular technologies. PCR-based testing remains widely adopted because of its speed and cost-effectiveness, while NGS continues expanding owing to its ability to simultaneously analyze multiple pharmacogenomic markers.

By gene family, testing focuses on CYP450 genes, HLA genes, TPMT genes, DPYD genes, UGT genes, and other pharmacogenomic markers. CYP450 testing remains the most widely utilized because these genes significantly influence the metabolism of numerous commonly prescribed medications.

By therapeutic area, the market includes oncology, psychiatry & mental health, cardiology, neurology, pain management, infectious diseases, and other therapeutic areas. Oncology represents the leading segment due to increasing adoption of biomarker-guided therapies, while psychiatry is emerging rapidly as clinicians seek to optimize antidepressant and antipsychotic prescribing.

By end user, the market serves hospitals & health systems, diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and other healthcare organizations. Diagnostic laboratories continue expanding pharmacogenomic testing capacity as personalized medicine becomes more widely implemented.

Market Trends

The pharmacogenomics testing market continues to evolve through innovation and expanding clinical adoption.

Key trends include:

Increasing integration of pharmacogenomics into routine clinical workflows.
Growing use of next-generation sequencing for multi-gene testing.
Expansion of companion diagnostics.
AI-powered clinical decision support systems.
Greater integration with electronic health records.
Rising investment in precision medicine initiatives.
Expansion of pharmacogenomic testing across primary care and specialty medicine.

Regional Insights

North America remains the largest pharmacogenomics testing market because of advanced healthcare infrastructure, widespread precision medicine adoption, favorable research funding, and strong regulatory support for pharmacogenomic biomarkers. Healthcare providers continue integrating genetic testing into oncology, cardiology, psychiatry, and primary care.

Europe maintains significant market growth through expanding genomic medicine programs, increasing implementation of personalized prescribing guidelines, and growing public investment in molecular diagnostics.

Asia-Pacific is expected to witness the fastest growth due to improving healthcare infrastructure, increasing genomic research, expanding precision medicine initiatives, and rising demand for advanced diagnostic technologies. China, Japan, South Korea, India, and Australia are major contributors to regional expansion.

Latin America and the Middle East & Africa are gradually strengthening pharmacogenomics capabilities through healthcare modernization, improving molecular diagnostic infrastructure, and increasing physician awareness.

Competitive Landscape

The market includes leading molecular diagnostics companies, sequencing technology providers, and precision medicine developers.

Major companies include Thermo Fisher Scientific, Illumina, QIAGEN, Abbott Laboratories, Agilent Technologies, Roche Diagnostics, Bio-Rad Laboratories, Revvity (PerkinElmer), Danaher Corporation, and Laboratory Corporation of America Holdings (Labcorp). Companies continue investing in multiplex testing panels, AI-enabled interpretation platforms, companion diagnostics, and strategic collaborations with healthcare organizations and pharmaceutical companies.

Future Outlook

The future of the pharmacogenomics testing market will be driven by broader clinical adoption of personalized medicine, increasing integration of pharmacogenomic information into prescribing guidelines, expansion of companion diagnostics, and advances in sequencing technologies. Artificial intelligence, clinical decision support software, and electronic health record integration are expected to improve interpretation and clinical implementation, supporting routine pharmacogenomic testing across multiple therapeutic areas.

Conclusion

The Global Pharmacogenomics Testing Market is expected to experience robust growth through 2031, supported by increasing demand for personalized medicine, expanding precision oncology programs, and continuous advances in molecular diagnostics. Although reimbursement variability, physician education, and interpretation complexity remain challenges, continued innovation in genomic technologies and clinical decision support is expected to create substantial opportunities for diagnostic manufacturers, pharmaceutical companies, healthcare providers, researchers, and investors.

Key Benefits of this Report

Comprehensive assessment of the global pharmacogenomics testing market.
Detailed evaluation of technologies, therapeutic applications, and emerging trends.
Analysis of competitive strategies, regulatory developments, and commercialization opportunities.
Insights into precision medicine, companion diagnostics, and AI-enabled clinical decision support.
Valuable resource for diagnostic companies, pharmaceutical manufacturers, healthcare providers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, precision medicine strategy, product portfolio planning, companion diagnostic development, competitive benchmarking, commercialization planning, partnership evaluation, investment analysis, regulatory planning, and long-term strategic decision-making.

Report Coverage

Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2031
Comprehensive analysis of the global pharmacogenomics testing market by product & service, technology, gene family, therapeutic area, end user, and geography
Evaluation of market dynamics, technology innovation, competitive landscape, reimbursement environment, and future growth opportunities
Assessment of PCR, DNA microarrays, next-generation sequencing, Sanger sequencing, clinical decision support software, companion diagnostics, precision medicine initiatives, and commercialization strategies
Analysis of CYP450 genes, HLA genes, TPMT genes, DPYD genes, UGT genes, oncology, psychiatry, cardiology, neurology, pain management, infectious diseases, hospitals, diagnostic laboratories, pharmaceutical companies, and emerging pharmacogenomics testing technologies through 2031.

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Pharmacogenomics Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Pharmacogenomics Ecosystem Overview
3.8 Precision Medicine and Personalized Therapy Landscape
3.9 Testing Volume Analysis
3.10 User Adoption Analysis
3.11 Drug-Gene Interaction Landscape
3.12 Companion and Complementary Diagnostics Overview
3.13 Clinical Utility and Healthcare Outcomes Assessment

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in Pharmacogenomics Testing
6.2 Product Innovation Analysis
6.3 Next-Generation Sequencing-Based Pharmacogenomics Advancements
6.4 Multiplex Genotyping and Panel Testing Innovations
6.5 Clinical Decision Support System Integration
6.6 Clinical Trial Analysis
6.7 Pipeline Analysis
6.8 AI Integration in Pharmacogenomic Interpretation
6.9 Digital Health and Electronic Health Record Integration
6.10 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Pharmacogenomics Testing Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Gene Family
8.3 Analysis by Testing Methodology
8.4 Analysis by Therapeutic Area
8.5 Analysis by Clinical Application
8.6 Analysis by Testing Setting
8.7 Analysis by End User

9. Pharmacogenomics Testing Market Segment Analysis (2021-2035)

9.1 By Product & Service
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software & Clinical Decision Support Solutions
- 9.1.4 Pharmacogenomic Testing Services
9.2 By Technology
- 9.2.1 Polymerase Chain Reaction (PCR)
- 9.2.2 DNA Microarrays
- 9.2.3 Next-Generation Sequencing (NGS)
- 9.2.4 Sanger Sequencing
- 9.2.5 Other Technologies
9.3 By Gene Family
- 9.3.1 CYP450 Genes
- 9.3.2 HLA Genes
- 9.3.3 TPMT Genes
- 9.3.4 DPYD Genes
- 9.3.5 UGT Genes
- 9.3.6 Other Pharmacogenomic Markers
9.4 By Therapeutic Area
- 9.4.1 Oncology
- 9.4.2 Psychiatry and Mental Health
- 9.4.3 Cardiology
- 9.4.4 Neurology
- 9.4.5 Pain Management
- 9.4.6 Infectious Diseases
- 9.4.7 Other Therapeutic Areas
9.5 By End User
- 9.5.1 Hospitals and Health Systems
- 9.5.2 Diagnostic Laboratories
- 9.5.3 Academic & Research Institutes
- 9.5.4 Pharmaceutical & Biotechnology Companies
- 9.5.5 Other End Users

10. Pharmacogenomics Testing Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Pharmacogenomics Testing Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Netherlands
11.7 Switzerland
11.8 China
11.9 Japan
11.10 South Korea
11.11 India
11.12 Australia
11.13 Brazil
11.14 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 QIAGEN N.V.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 F. Hoffmann-La Roche Ltd
13.3 Thermo Fisher Scientific Inc.
13.4 Illumina, Inc.
13.5 Myriad Genetics, Inc.
13.6 Natera, Inc.
13.7 Labcorp Holdings Inc.
13.8 Quest Diagnostics Incorporated
13.9 SOPHiA GENETICS SA
13.10 Bio-Rad Laboratories, Inc.
13.11 Invitae Corporation
13.12 Genomind, Inc.
13.13 OneOme, LLC
13.14 GeneDx, LLC
13.15 Molecular You Corporation